A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice

舍曲林 西酞普兰 评定量表 萧条(经济学) 随机对照试验 心理学 不利影响 内科学 临床试验 医学 麻醉 精神科 抗抑郁药 焦虑 经济 宏观经济学 发展心理学
作者
Lisa Ekselius,Lars von Knorring,G. Eberhard
出处
期刊:International Clinical Psychopharmacology [Wolters Kluwer]
卷期号:12 (6): 323-332 被引量:95
标识
DOI:10.1097/00004850-199711000-00005
摘要

The purpose of this double-blind, multicenter trial was to compare the efficacy and safety of sertraline (50-150 mg/day) with those of citalopram (20-60 mg/day) in patients with major depression in general practice during 24 weeks of treatment. The patients were assessed using the Montgomery-Asberg Depression Rating Scale and the Clinical Global Impressions of severity and improvement scales. Observed and spontaneously reported adverse events were recorded and side-effects were assessed by means of the UKU Side-Effect Scale. Altogether 400 patients were randomized into the study. A total of 308 patients completed the 24-week study in accordance with the protocol. A significant reduction in the total Montgomery-Asberg Depression Rating Scale scores was observed in both treatment groups as early as 2 weeks, with no statistically significant differences between the drugs. In the intention to treat-last observation carried forward analysis 76% responded to treatment in the sertraline and 81% in the citalopram group. The final mean doses were 82 mg/day (64% higher than baseline) in the sertraline group and 34 mg/day (70% higher than baseline) in the citalopram group. The response rate in completers in accordance with protocol was 90% in the sertraline group and 93% in the citalopram group. The side-effects were those usually seen, and both sertraline and citalopram were considered to be well tolerated. It was concluded that patients with major depression in general practice respond well to 24 weeks of treatment with sertraline or citalopram. With regard to efficacy, no statistically significant differences were found between the drugs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
新楚完成签到 ,获得积分10
2秒前
兴奋迎彤完成签到,获得积分10
2秒前
焦小黑发布了新的文献求助10
2秒前
害羞的可燕完成签到,获得积分10
2秒前
小陈发布了新的文献求助10
3秒前
123456发布了新的文献求助20
3秒前
奚瑞完成签到,获得积分10
4秒前
一去二三里完成签到,获得积分10
4秒前
坦率秀完成签到,获得积分10
5秒前
Akim的应助被科研通管家采纳,获得30
5秒前
852的应助被科研通管家采纳,获得10
5秒前
sakiko_togawa完成签到,获得积分10
5秒前
CodeCraft的应助被科研通管家采纳,获得10
5秒前
5秒前
领导范儿的应助被科研通管家采纳,获得10
5秒前
英姑的应助被笑点低的海冬采纳,获得10
5秒前
syvshc的应助被科研通管家采纳,获得10
5秒前
康康77的应助被科研通管家采纳,获得10
5秒前
6秒前
6秒前
SciGPT的应助被科研通管家采纳,获得10
6秒前
FashionBoy的应助被科研通管家采纳,获得10
6秒前
在水一方的应助被科研通管家采纳,获得10
6秒前
勤奋一一的应助被科研通管家采纳,获得10
6秒前
Tang发布了新的文献求助10
6秒前
CipherSage的应助被科研通管家采纳,获得30
6秒前
无极微光的应助被科研通管家采纳,获得20
6秒前
共享精神的应助被科研通管家采纳,获得10
7秒前
syvshc的应助被科研通管家采纳,获得10
7秒前
淡定雁玉发布了新的文献求助10
7秒前
清辉影的应助被MADAO采纳,获得30
7秒前
7秒前
852的应助被六百六十六采纳,获得10
8秒前
彭于晏的应助被zz采纳,获得10
8秒前
AireenBeryl531的应助被快乐十一采纳,获得10
8秒前
小马发布了新的文献求助10
9秒前
翟思宇发布了新的文献求助10
9秒前
小巧的绮发布了新的文献求助10
11秒前
Amber完成签到,获得积分20
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181940
求助须知:如何正确求助?哪些是违规求助? 9571697
关于积分的说明 21819181
捐赠科研通 7778330
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557767
邀请新用户注册赠送积分活动 2479621